Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

BACKGROUND: Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selective peroxisome proliferator-activated receptor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Diabetol
Päätekijät: Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8097867/
https://ncbi.nlm.nih.gov/pubmed/33947390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01291-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia